Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine

Teodora Pene Dumitrescu¹, Kavita Peddiraju², Caifeng Fu³, Kalpana Bakshi², Shui Yu³, Zhiping Zhang³, Allan R. Tenorio⁴, Chris Spancake⁵, Shashidhar Joshi⁶, Allen Wolstenholme², and Kimberly Adkison⁷

Abstract
This single-dose study evaluated the bioequivalence, food effect, and safety of 2 experimental, 2-drug, fixed-dose formulations of 50 mg dolutegravir and 300 mg lamivudine (formulation AH and formulation AK) as compared with coadministration of single-entity tablets of 50 mg dolutegravir and 300 mg lamivudine (reference). In fasted subjects, formulation AH lamivudine exposure was similar to the reference; however, dolutegravir exposure was consistently higher in formulation AH, with area under the concentration-time curve (AUC) and maximum concentration (Cmax) approximately 27% to 28% greater than reference. Formulation AK met bioequivalence standards to the reference for dolutegravir (AUC₀₋₂ and Cmax) and lamivudine (AUC₀₋₂ and AUC₀₋₇) exposure; however, dolutegravir AUC₀₋₇ and lamivudine Cmax were approximately 16% and 32% higher than the reference, respectively. A high-fat meal increased dolutegravir AUC and Cmax by up to 33% and 21%, respectively, and decreased lamivudine Cmax by approximately 30%. Both test and reference formulations were well tolerated. The results support further development of formulation AK as a novel, 2-drug, fixed-dose combination tablet treatment for patients with HIV.

Keywords
bioequivalence, dolutegravir, HIV, lamivudine

The standard of care for patients infected with human immunodeficiency virus 1 (HIV-1) is a life-long regimen of 3 or more antiretroviral agents: 2 nucleoside reverse transcriptase inhibitors and a third drug from one of the following classes: protease inhibitors, integrase inhibitors, or nonnucleoside reverse transcriptase inhibitors.¹ Multidrug regimens that require multiple tablets or capsules, especially with different dosing times, can suffer from decreased adherence and, consequently, reduced therapeutic efficacy.²⁻⁴ Contemporary regimens consist of fixed-dose combinations of 2 or 3 drugs that are convenient to take, provide durable virologic suppression, and are relatively well tolerated. In addition, fixed-dose combination tablets have been shown to enhance patient adherence to a life-long treatment regimen and, consequently, to improve patient outcomes.²⁻⁴⁻⁵

Two drugs currently used in HIV treatment are dolutegravir and lamivudine. Dolutegravir is a potent HIV integrase strand transfer inhibitor⁶ with a high barrier for viral resistance⁷ that does not require pharmacokinetic boosting and can be administered once daily.⁶⁻⁹ Dolutegravir is rapidly absorbed when administered orally (time to peak concentration [tmax] from 0.5 to 2 hours¹⁰) and has demonstrated dose proportionality for exposure (area under the concentration-time curve [AUC]) over the range

¹ Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Collegeville, Pennsylvania, USA
² Pharma R&D, GlaxoSmithKline, Collegeville, Pennsylvania, USA
³ PAREXEL International, Durham, North Carolina, USA
⁴ Clinical Development, ViiV Healthcare, Durham, North Carolina, USA
⁵ Medicinal Science and Technology, GlaxoSmithKline, Collegeville, Pennsylvania, USA
⁶ Biostatistics, GlaxoSmithKline India, Mumbai, India
⁷ Clinical Pharmacology, ViiV Healthcare, Durham, North Carolina, USA

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Submitted for publication 13 February 2019; accepted 26 August 2019.

Corresponding Author:
Teodora Pene Dumitrescu, PhD, GlaxoSmithKline, 1250 S Collegeville Rd, Collegeville, PA 19426.
(e-mail: Teodora.x.pene-dumitrescu@gsk.com)
of 2 to 100 mg for a single dose oral suspension. In a mass balance study of 20 mg [14C]-dolutegravir (80 µCi), unchanged dolutegravir was the predominant component in plasma, with elimination occurring in both feces and in urine (64.0% and 31.6% of dolutegravir recovered, respectively). The primary metabolic pathway for dolutegravir is conversion to a pharmacologically inactive ether glucuronide by UDP-glucuronosyltransferase (UGT) 1A1. Other minor biotransformation pathways include oxidation by cytochrome P450 3A4 and metabolism by UGT1A3 and UGT1A9. Because dolutegravir is a substrate for P-glycoprotein and breast cancer resistance protein in vitro. Lamivudine is highly soluble and rapidly absorbed (tmax from 0.5 to 4.0 hours), with absolute bioavailability ranging from 82% to 86% for oral administration. The majority of lamivudine is renally excreted, with approximately 70% of an administered oral dose eliminated as unchanged drug in urine over 24 hours. In particular, lamivudine is eliminated by filtration and active renal tubular secretion. Metabolism is a minor route of elimination, with only 5% to 10% of the parent drug metabolized to an inactive transsulfoxide metabolite that is excreted in the urine. In peripheral blood mononuclear cells, lamivudine is anabolized by phosphorylation to lamivudine triphosphate, the molecule required for antiviral activity. Lamivudine has demonstrated few interactions with cytochrome P450 enzymes, although drugs that are also renally excreted have the potential for interactions with lamivudine. Coadministration of trimethoprim sulfamethoxazole increases lamivudine exposure (AUC0-∞) by 43%; however, the increase is unlikely to result in toxicity based on the safety profile of higher lamivudine doses up to 300 mg administered twice daily. Coadministration with sorbitol decreases the absorption of lamivudine, with AUC0-∞ being reduced by 14% to 36% and maximum concentration (Cmax) by 28% to 55%.

Currently, dolutegravir and lamivudine are individually approved in the United States as Tivicay (ViiV Healthcare, Research Triangle Park, North Carolina) and Epivir (ViiV Healthcare, respectively). These drugs are also available as a single tablet fixed-dose formulation with abacavir under the brand name Truumeq (ViiV Healthcare). Two large, multicenter, double-blind, randomized, noninferiority studies in treatment-naive, HIV-infected adults (GEMINI-1 and -2) recently evaluated dolutegravir and lamivudine as a 2-drug regimen, with each coadministered as an individual tablet. The GEMINI studies compared once-daily coadministration of 50 mg dolutegravir plus 300 mg lamivudine to a standard of care, once-daily, 3-drug regimen consisting of a 50-mg dolutegravir tablet plus a 2-drug, fixed-dose tablet containing 300 mg tenofovir disoproxil fumarate and 200 mg emtricitabine. The 2-drug regimen was found to be noninferior to the 3-drug regimen and was well tolerated.

To pursue new fixed-dose tablet formulations, development was initiated for a 2-drug single tablet containing 50 mg dolutegravir and 300 mg lamivudine. Two early formulations, formulations AA and AB, were developed, and the relative bioavailability assessed as part of a single-dose, fasted, 3-way crossover study with 6 treatment sequences (Study 204993, ClinicalTrials.gov Identifier NCT02738931; results published on the clinical trial registry). These formulations (test) were compared with coadministration of individual 50-mg dolutegravir and 300-mg lamivudine tablets (reference). Both fixed-dose combination formulations were safe and well tolerated. Exposure (based on AUC and Cmax) to dolutegravir in formulation AA was 12% to 14% greater than the reference, and lamivudine Cmax was approximately 18% greater than the reference. The current article summarizes the findings of a bioequivalence study comparing the experimental formulations AH and AK tablets (test) to coadministration of 50-mg dolutegravir and 300-mg lamivudine.
Figure 1. Study design for Study 204994 to assess the bioequivalence and food effect of 2 experimental formulations of fixed-dose combination tablets (formulation AH, part 1, and AK, part 2) containing 50 mg dolutegravir and 300 mg lamivudine. Reference regimen administration was coadministration of individual, single-entity tablets of 50 mg dolutegravir plus 300 mg lamivudine. Both parts of the study had equivalent designs: an open-label, crossover design in which 76 subjects (planned) were randomized 1:1 to receive test or reference treatment in periods 1 and 2. In period 3, 16 subjects who had completed period 1 and period 2 also completed the food-effect study, in which the test formulation was administered with a high-fat meal. In part 1, subjects were administered formulation AH as the test drug. In part 2, a separate cohort of subjects received formulation AK.

Methods
Study Design and Treatment
The protocol for this study, Study 204994 (ClinicalTrials.gov Identifier NCT03078556), was approved by the Midlands Independent Review Board (Overland Park, Kansas). This study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. All volunteers gave written informed consent. Study treatment was conducted at a single US site at Quintiles Phase One Services (Overland Park, Kansas).

This was a randomized, open-label, 2-part study, with 3 treatment periods per part, designed to evaluate the bioequivalence and food effect of 2 experimental fixed-dose combination tablet formulations, formulation AH (part 1 test formulation) and formulation AK (part 2 test formulation). The study design is shown in Figure 1, with the design replicated for separate cohorts in part 1 and part 2. Comparison was to a reference treatment consisting of coadministration of 1 50-mg dolutegravir tablet and 1 300-mg lamivudine tablet.

The first 2 treatment periods (periods 1 and 2) in each part were randomized, crossover periods in which 76 subjects (randomized in a 1:1 ratio to test-reference or reference-test) received a single oral dose of the test or reference treatment. In periods 1 and 2, test and reference drugs were administered in the fasted state (after at least a 10-hour fast) with 240 mL of room-temperature water.

In the third treatment period, 16 subjects who had participated in and completed both periods 1 and 2 and who provided consent returned to receive a single dose of the fixed-dose combination test formulation administered with a standard high-fat meal as defined by the US Food and Drug Administration, which includes approximately 150, 250, and 500 to 600 dietary calories (kcal) from protein, carbohydrate, and fat, respectively.

Each period was separated by at least 7 days of washout.

Investigational Products
The reference regimen included 1 tablet of dolutegravir (50 mg) and 1 tablet of lamivudine (300 mg). Dolutegravir tablets contained 50 mg dolutegravir, mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, sodium stearyl fumarate, and were coated with a poly(vinyl alcohol)-based film coat. Lamivudine tablets were provided as commercially available lamivudine tablets and contained 300 mg lamivudine, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, and were coated with a hydroxypropyl methylcellulose–based film coat.

Formulations AH and AK were 2-drug, fixed-dose, single-tablet formulations, and both contained 50 mg dolutegravir, 300 mg lamivudine, mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, sodium stearyl fumarate, and were coated with a hydroxypropyl methylcellulose–based film coat. Formulation AK additionally contained magnesium stearate.

Study Population
Eligible subjects were healthy men and women between the ages of 18 and 55 years (inclusive) with a body mass index within the range of 18.5 to 31.0 kg/m² (inclusive); men and women were at least 50 kg and 45 kg, respectively. Overall health was determined by medical history, physical examination, 12-lead ECG, and laboratory tests. Women were enrolled only if they were of nonchildbearing potential or of childbearing potential, had a negative pregnancy test, and agreed to follow
approved guidelines for contraception. Subjects had to possess the ability to swallow 2 tablets at the same time for administration of the reference treatment.

Subjects were excluded from the study if they had alanine aminotransferase (ALT) or bilirubin > 1.5 times the upper limit of normal (ALT normal range, 21 to 72 IU/L; bilirubin normal range, 3.42 to 22.23 µmol/L); had a chronic history of liver disease or known hepatic/biliary abnormalities (except for Gilbert syndrome or asymptomatic gallstones); had a QT interval corrected for heart rate according to the Fredericia formula (QTcF) > 450 ms; had a history of regular alcohol consumption (> 14 drinks/wk for men and > 7 drinks/wk for women) within 6 months of the study; had creatinine clearance < 60 mL/min, indicating renal impairment; tested positive for either HIV, hepatitis B or hepatitis C virus; were current illicit drug users; or had a history or regular use of tobacco- or nicotine-containing products within 1 month before screening; or had a history of sensitivity indicative of smoking or a history or regular use of both medications.

**Sample Size Calculation**

A sample size of 70 subjects was calculated to provide a 90% power to demonstrate bioequivalence for the fixed-dose combination formulation compared with the reference treatment. The estimates of likely inter-subject variability (coefficients of within-subject variation, CVw%) and true geometric least-squares (GLS) mean ratios were based on study 204993, which evaluated the relative bioavailability of early-stage fixed-dose formulations. The sample size calculation assumed a 90% power to demonstrate bioequivalence for the fixed-dose combination formulation compared with those for lamivudine (CVw% of 9.0% to 20%).

Overall, the study enrolled 76 subjects such that a minimum of 70 evaluable subjects would complete treatment periods 1 and 2. Additional subjects were enrolled to account for subject attrition and unevaluable pharmacokinetic parameters.

**Pharmacokinetic Sampling and Bioanalytical Methods**

Blood samples for pharmacokinetic sampling were taken predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours postdose for all periods. Plasma samples were analyzed for dolutegravir and lamivudine concentrations by Pharmaceutical Product Development (PPD; Middleton, Wisconsin) using a validated analytical method.

Dolutegravir was extracted from plasma using protein precipitation with acetonitrile containing the stable isotope-labeled dolutegravir internal standard (GSK1349572-d7-15N), followed by analysis with ultra-performance liquid chromatography (Acquity UPLC, Waters, Milford, Massachusetts) tandem mass spectrometry using isocratic elution with 60% of 0.1% formic acid in water and 40% of 0.1% formic acid in acetonitrile on a Waters XBridge BEH C18 column (130 Å, 3.5 µm, 2.1 × 50 mm; room temperature; flow rate 0.475 mL/min for 1.50 minutes) and using an API 4000 mass spectrometer (SCIEX, Framingham, Massachusetts) with a turbo ion spray interface in positive ion electrospray mode. The lower and upper limits of quantification for dolutegravir were 20 ng/mL and 20000 ng/mL, respectively, using a 25-µL aliquot of human plasma (K2EDTA anticoagulant). Precision and accuracy were evaluated as described in Song et al.28 Mass spectrometry was set with multiple reaction monitoring (m/z 428.02 to m/z 277.10 for the internal standard and m/z 420.00 to m/z 283.10 for dolutegravir).

Lamivudine and the internal standard [13C, 15N2]-lamivudine were extracted from plasma using protein precipitation, followed by analysis with high-performance liquid chromatography using a Thermo Scientific BetaSil Silica 100 column [100 Å, 5 µm, 3.0 × 50 mm] and an LC-30AD liquid chromatography pump (Shimadzu, Kyoto, Japan) with binary mobile-phase gradient elution at room temperature (Mobile Phase A, 10 mmol/L ammonium formate with 0.1% formic acid in water; and Mobile Phase B, 0.1% formic acid in acetonitrile) and a stepwise flow rate of 0.65 mL/min to 1 mL/min. The initial mobile phase condition of 10:90 (A:B) at 0.65 mL/min was held for 1.7 minutes, adjusted to 50:50 at 1.0 mL/min from 1.8 to 2.8 minutes, held at 10:90 and 0.65 mL/min for 1 minute, and finally returned to 10:90 at 0.65 mL/min (total run time of 4 minutes per sample). Detection was performed using an API 3000 mass spectrometer (SCIEX, Framingham, Massachusetts) with triple quadrupole mass spectrometry and a turbo ion spray interface in positive ion electrospray mode. The assay had lower and upper limits of quantification of 2.5 ng/mL and 2500 ng/mL, respectively, using a 50-µL aliquot of K2EDTA plasma. Precision and accuracy were evaluated using quality control samples as described by Adkison et al.23 Mass spectrometry was set with multiple reaction monitoring (m/z 233.0 for the internal standard and m/z 230.0 for lamivudine).
Pharmacokinetic Analyses

The pharmacokinetic plasma concentration population included all subjects who underwent plasma pharmacokinetic sampling and had evaluable dolutegravir or lamivudine concentration results sufficient to calculate pharmacokinetic parameters. The pharmacokinetic parameter bioequivalence summary population included subjects who had evaluable pharmacokinetic parameters for both analytes for both periods 1 and 2. The pharmacokinetic parameter food summary population included all subjects who had evaluable pharmacokinetic parameters for both the fed and fasted states for their corresponding test formulation (AH or AK). Data from subjects who vomited within 4 hours of study drug administration were not considered as evaluable.

Separate pharmacokinetic parameters for dolutegravir and lamivudine were derived using noncompartmental analysis methods and actual sampling times with Phoenix WinNonlin v6.3 (Certara, LP, Princeton, New Jersey). From the plasma concentration-time data, the pharmacokinetic parameters determined for each of the 2 analytes included Cmax, tmax, AUC0−t, AUC0∞, AUC0−24, half-life (t1/2), apparent clearance, and lag time. AUC0−∞, AUC0−t, and Cmax were used as primary end points for bioequivalence.

Statistical Analyses

SAS version 9.4 (SAS Institute, Cary, North Carolina) was used for statistical analysis. Pharmacokinetic parameters for dolutegravir and lamivudine (except for tmax and lag time) were loge-transformed and analyzed with analysis of variance methods and actual sampling times. Pharmacokinetic parameters were derived using noncompartmental analysis methods and actual sampling times with Phoenix WinNonlin v6.3 (Certara, LP, Princeton, New Jersey). From the plasma concentration-time data, the pharmacokinetic parameters determined for each of the 2 analytes included Cmax, tmax, AUC0−t, AUC0∞, AUC0−24, half-life (t1/2), apparent clearance, and lag time. AUC0−∞, AUC0−t, and Cmax were used as primary end points for bioequivalence.

Results

Subject Disposition and Demographics

A total of 154 subjects (78 subjects in part 1 and 76 subjects in part 2) were enrolled and randomized, with 147 completing the study (73 subjects in part 1 and 74 subjects in part 2). Sixteen subjects who completed treatment periods 1 and 2 and provided consent continued and participated in the food effect portion of the study. Approximately two thirds of the subjects enrolled in the study were male, and the majority were white (65%) and not Hispanic or Latino (90%). The mean age of the study population was 30.5 ± 10.3 years (range 18 to 55 years), with an overall mean body mass index of 25.7 ± 3.3 kg/m². The demographics were comparable between subjects in part 1 and part 2 (Table 1).

Pharmacokinetics and Bioequivalence

The dolutegravir and lamivudine mean concentration-time profiles for formulations AH and AK compared with the reference are shown in Figure 2. The statistical comparison of plasma dolutegravir and lamivudine concentration-time profiles for formulations AH and AK compared with the reference are shown in Table 2. For formulation AH, dolutegravir plasma AUC0−∞, AUC0−t, and Cmax were 16% to 28% higher than the reference. This observation was similar to the increased dolutegravir exposure noted with fixed-dose combination...
Table 1. Disposition and Demographics for Study Subjects in Part 1, Part 2, and Overall

| Parameter                          | Part 1 | Part 2 | Total   |
|------------------------------------|--------|--------|---------|
| **Subject disposition**            |        |        |         |
| Number of subjects                 | 78     | 76     | 154     |
| Number of subjects completed as planned, n (%) | 73 (94%) | 74 (97%) | 147 (95%) |
| Number of subjects withdrawn (any reason), n (%) | 5 (6%) | 2 (3%) | 7 (5%) |
| Reasons for subject withdrawal, n (%) |        |        |         |
| Lost to follow-up                  | 2 (3%) | 1 (1%) | 3 (2%) |
| Adverse events                     | 2 (3%) | 1 (1%) | 3 (2%) |
| Physician decision¹                | 1 (1%) | 0      | 1 (<1%) |
| **Subject demographics**           |        |        |         |
| Age, y, mean (SD)                  | 29.4 (9.37) | 31.6 (11.18) | 30.5 (10.33) |
| Sex, n (%)                         |        |        |         |
| Female                             | 25 (32%) | 26 (34%) | 51 (33%) |
| Male                               | 53 (68%) | 50 (66%) | 103 (67%) |
| BMI, kg/m², mean (SD)              | 25.51 (3.204) | 25.83 (3.354) | 25.67 (3.272) |
| Height, cm, mean (SD)              | 171.97 (8.381) | 172.05 (8.592) | 172.01 (8.458) |
| Weight, kg, mean (SD)              | 75.69 (12.476) | 76.57 (12.122) | 76.12 (12.270) |
| Ethnicity, n (%)                   |        |        |         |
| Hispanic or Latino                 | 11 (14%) | 4 (5%) | 15 (10%) |
| Not Hispanic or Latino             | 67 (86%) | 72 (95%) | 139 (90%) |
| Race, n (%)                        |        |        |         |
| Black or African American          | 20 (26%) | 23 (30%) | 43 (28%) |
| American Indian or Alaskan Native  | 6 (8%) | 1 (1%) | 7 (5%) |
| Asian, East Asian Heritage         | 0      | 1 (1%) | 1 (<1%) |
| Asian, Central/South Asian Heritage| 1 (1%) | 1 (1%) | 2 (1%) |
| Asian, Southeast Asian Heritage    | 1 (1%) | 0      | 1 (<1%) |
| White, White/European Heritage     | 50 (64%) | 50 (66%) | 100 (65%) |

BMI indicates body mass index.

¹One subject was removed from the study due to elevated alanine aminotransferase and aspartate aminotransferase associated with alcohol use (subject had a positive alcohol breath test).

formulations evaluated in a previous study (Study 204993). Therefore, formulation AH did not meet bioequivalence criteria for dolutegravir exposure. Exposure parameters (C<sub>max</sub> and AUC) for lamivudine met established bioequivalence criteria, with the 90%CI of the GLS mean ratio falling between 0.80 and 1.25.

For formulation AK, dolutegravir met the established GLS mean ratio bioequivalence criteria for AUC<sub>0-∞</sub> and C<sub>max</sub>. The AUC<sub>0-t</sub> value for dolutegravir for formulation AK was ~16% higher than that of the reference, with the upper limit of the 90%CI slightly above 1.25 (1.2507). However, 2 subjects had between-treatment differences in t<sub>last</sub> (48 hours versus 72 hours) that resulted in a different time window for the calculation of AUC<sub>0-t</sub>. When these 2 subjects were excluded in an ad hoc sensitivity analysis, the dolutegravir
Table 2. Statistical Comparison of Plasma Dolutegravir and Lamivudine PK Parameters for Bioequivalence in the Fasted State

| Parameter          | Statistic       | Formulation AH (Part 1) | Formulation AK (Part 2) |
|--------------------|-----------------|-------------------------|-------------------------|
|                    | Test (n = 73)   | Reference (n = 73)      | GLS Mean Ratio (90%CI of the Ratio) [%CVw] |
|                    | GLS Mean Ratio (90%CI of the Ratio) [%CVw] |
|                    | Reference (n = 74) | GLS Mean Ratio (90%CI of the Ratio) [%CVw] | |
| Dolutegravir       |                 |                         |                         |
| AUC<sub>0-24</sub>, h·µg/mL | Mean (SD) | 57.395 (16.654) | 46.156 (16.753) | 57.236 (17.860) | 50.755 (19.188) | 54.559 | 47.239 | 1.1550 (1.0699, 1.2468) |
|                    | Adjusted geomean | 54.858 | 43.162 | 1.2710 (1.1894, 1.3582) | 54.802 (16.734) | 48.441 (17.890) | 52.337 | 45.204 | 1.1578 (1.0718, 1.2507) |
|                    |                 |                         |                         |
| AUC<sub>0-24</sub>, h·µg/mL | Mean (SD) | 55.236 (15.836) | 44.301 (15.956) | 54.802 (16.734) | 48.441 (17.890) | 52.337 | 45.204 | 1.1578 (1.0718, 1.2507) |
|                    | Adjusted geomean | 52.856 | 41.436 | 1.2756 (1.1919, 1.3651) | 52.337 | 45.204 | 1.1578 (1.0718, 1.2507) |
|                    |                 |                         |                         |
| AUC<sub>0-24</sub>, h·µg/mL | Adjusted geomean | 53.588<sup>a</sup> | 43.207<sup>a</sup> | 1.2403 (1.1604, 1.3257) | 53.588<sup>a</sup> | 43.207<sup>a</sup> | 1.2403 (1.1604, 1.3257) |
|                    |                 |                         |                         |
| C<sub>max</sub>, µg/mL | Mean (SD) | 39.224 (11.198) | 31.364 (10.921) | 38.269 (11.376) | 33.611 (11.694) | 36.163 | 31.566 | 1.1599 (1.0711, 1.2560) |
|                    | Adjusted geomean | 37.600 | 29.435 | 1.2774 (1.1931, 1.3676) | 37.600 | 29.435 | 1.2774 (1.1931, 1.3676) |
|                    |                 |                         |                         |
| CL/F, L/h          | Mean (SD) | 3.231 (1.007) | 2.566 (0.869) | 3.040 (0.871) | 2.703 (0.868) | 2.913 | 2.553 | 1.1410 (1.0533, 1.2361) |
|                    | Adjusted geomean | 3.082 | 2.407 | 1.2805 (1.1890, 1.3790) | 3.082 | 2.407 | 1.2805 (1.1890, 1.3790) |
|                    |                 |                         |                         |
| Lamivudine         |                 |                         |                         |
| AUC<sub>0-24</sub>, h·µg/mL | Mean (SD) | 3.231 (1.007) | 2.566 (0.869) | 3.040 (0.871) | 2.703 (0.868) | 2.913 | 2.553 | 1.1410 (1.0533, 1.2361) |
|                    | Adjusted geomean | 3.082 | 2.407 | 1.2805 (1.1890, 1.3790) | 3.082 | 2.407 | 1.2805 (1.1890, 1.3790) |
|                    |                 |                         |                         |
| AUC<sub>0-24</sub>, h·µg/mL | Mean (SD) | 13.004 (2.562) | 12.572 (2.490) | 13.773 (2.430) | 12.985 (2.365) | 13.588<sup>c</sup> | 12.771<sup>c</sup> | 1.0638 (1.0416, 1.0865) |
|                    | Adjusted geomean | 12.757 | 12.337 | 1.0341 (1.0097, 1.0591) | 12.757 | 12.337 | 1.0341 (1.0097, 1.0591) |
|                    |                 |                         |                         |
| (Continued)
| Parameter | Statistic | Test (n = 73) | Reference (n = 73) | GLS Mean Ratio (90% CI of the Ratio) [%CVw] | Test (n = 74) | Reference (n = 74) | GLS Mean Ratio (90% CI of the Ratio) [%CVw] |
|-----------|-----------|--------------|-------------------|---------------------------------|--------------|-------------------|---------------------------------|
|           |           | Mean (SD)    |                   | GLS Mean Ratio (90% CI of the Ratio) [%CVw] |              |                   | GLS Mean Ratio (90% CI of the Ratio) [%CVw] |
|           |           |              |                   | GLS Mean Ratio (90% CI of the Ratio) [%CVw] |              |                   | GLS Mean Ratio (90% CI of the Ratio) [%CVw] |
| AUC0-24, h·µg/mL | Mean (SD) | 12.178 (2.451) | 11.637 (2.400) | 1.0475 (1.0185, 1.0773) [10.2] | 12.790 (2.340) | 11.870 (2.331) | 1.0807 (1.0539, 1.1081) [9.2] |
|           | Adjusted  | 11.940 | 11.398 | 1.0475 (1.0185, 1.0773) [10.2] | 12.581 | 11.642 | 1.0807 (1.0539, 1.1081) [9.2] |
|           | geomean   |              |                   | GLS Mean Ratio (90% CI of the Ratio) [%CVw] |              |                   | GLS Mean Ratio (90% CI of the Ratio) [%CVw] |
| AUC0-t, h·µg/mL | Mean (SD) | 12.855 (2.535) | 12.398 (2.479) | ... | 13.567 (2.425) | 12.700 (2.386) | ... |
|           | Adjusted  | 12.612 | 12.160 | ... | 13.355 | 12.479 | ... |
|           | geomean   | 12.685d | 12.253d | 1.0353 (1.0094, 1.0618) [9.0] | 13.409d | 12.526d | 1.0705 (1.0460, 1.0956) [8.3] |
| Cmax, µg/mL | Mean (SD) | 3.308 (0.898) | 2.773 (0.808) | ... | 3.350 (0.951) | 2.534 (0.677) | ... |
|           | Adjusted  | 3.187 | 2.666 | ... | 3.219 | 2.443 | 1.3176 (1.2616, 1.3760) [15.9] |
|           | geomean   |              |                   | GLS Mean Ratio (90% CI of the Ratio) [%CVw] |              |                   | GLS Mean Ratio (90% CI of the Ratio) [%CVw] |
| CL/F, L/h | Mean (SD) | 23.959 (4.732) | 24.793 (4.915) | 1.1956 (1.1437, 1.2498) [16.2] | 22.475 (4.166) | 23.896 (4.585) | 1.3176 (1.2616, 1.3760) [15.9] |
|           | Adjusted  | 23.516 | 24.318 | 0.9670 (0.9442, 0.9904) [8.7] | 22.080 | 23.489 | 0.9400 (0.9204, 0.9601) [7.7] |
|           | geomean   |              |                   | GLS Mean Ratio (90% CI of the Ratio) [%CVw] |              |                   | GLS Mean Ratio (90% CI of the Ratio) [%CVw] |
| tmax, h | Median    | 1.001 (0.500, 3.500) | 1.005 (0.500, 4.005) | -0.126 (-0.253, -0.01) | 1.001 (0.500, 3.500) | 1.006 (0.500, 4.002) | -0.248 (-0.376, -0.01) |
|           | Adjusted  | 18.144 (4.659) | 18.252 (5.273) | 18.621 | 19.210 | 0.9693 (0.9214, 1.0198) [18.6] |
|           | geomean   | 17.646 | 17.585 | 1.0353 (0.9536, 1.0559) [18.6] | 17.646 | 17.585 | 1.0353 (0.9536, 1.0559) [18.6] |

AUC indicates area under the concentration-time curve; CL/F, apparent clearance; Cmax, peak concentration; GLS, geometric least squares; PK, pharmacokinetic; %CVw, within-subject coefficient of variation expressed as a percentage; tmax, time to Cmax; t½, half-time of elimination.

Note: The adjusted geometric mean is the antilog of the adjusted mean (ls-mean) of log-transformed values, where ls-mean can be defined as a linear combination (sum) of the estimated effects from a linear model. GLS mean ratio calculated as test (experimental formulation) vs reference (coadministration of 50 mg dolutegravir plus 300 mg lamivudine).

- Five subjects had within-subject differences in dolutegravir tlast between treatments. Four subjects had tlast of 48 hours in the reference treatment arm and tlast of 72 hours in the test arm; 1 subject had tlast of 48 hours in the test arm and tlast of 72 hours in the reference arm. An ad hoc sensitivity analysis was conducted by excluding these subjects from analysis (n = 68).
- Two subjects had within-subject differences in dolutegravir tlast between treatments (tlast of 48 hours in the reference treatment arm and tlast of 72 hours in the test arm). An ad hoc sensitivity analysis was conducted by excluding these subjects from analysis (n = 68).
- One subject had a result not being determined for the reference treatment in part 2 because this subject had a time interval for determination of t½ < 2 × the estimated t½ and the percentage AUC extrapolated was > 20% (n = 73). Geometric mean analysis and bioequivalence analysis are reported with this subject's data excluded for the test formulation.
- Three subjects had between-treatment differences in lamivudine tlast (tlast of 48 hours in the reference treatment arm and tlast of 72 hours in the test arm). An ad hoc sensitivity analysis was conducted by excluding these subjects from analysis (n = 70).
- Two subjects had between-treatment differences in lamivudine tlast. One subject had tlast of 48 hours in the reference treatment arm and tlast of 72 hours in the test arm; the other subject had tlast of 48 hours in the test arm and tlast of 72 hours in the reference arm. An ad hoc sensitivity analysis was conducted by excluding these subjects from analysis (n = 72).
- tmax statistical comparison is estimated median difference, calculated as Test – Reference (90% CI for the difference).
Figure 3. Arithmetic mean (standard error of mean) plasma concentration-time curves for the analytes dolutegravir and lamivudine after administration of formulation AH (left) or formulation AK (right) in the fed and fasted states. Solid lines are given for the treatment administered in the fasted state, and dotted lines are given for treatment administered in the fed state. AH and AK respectively indicate formulations AH and AK; DTG, dolutegravir; 3TC, lamivudine.

AUC_{0-t} GLS means ratio met bioequivalence criteria, with a ratio (90%CI) of 1.1354 (1.0527, 1.2246). AUC end points for lamivudine (AUC_{0-\infty} and AUC_{0-t}) met established bioequivalence criteria on initial analysis and after sensitivity analysis. Lamivudine C_{max} was approximately 32% higher than the reference.

One subject was excluded from the calculation of lamivudine AUC_{0-\infty}, clearance, and t_{1/2} for the test formulation (AK) in part 2, as the λz time duration was less than twice the calculated t_{1/2}, and more than 20% of AUC_{0-\infty} was extrapolated. This subject was also excluded from the adjusted geometric mean analysis and subsequently excluded from the bioequivalence analysis for lamivudine AUC_{0-\infty}.

Food Effect
The dolutegravir and lamivudine mean concentration-time profiles in fed and fasted status for formulations AH and AK are shown in Figure 3. Pharmacokinetic parameters for experimental formulations given to subjects after at least a 10-hour fast (fasted) or following consumption of a standard high-fat meal (fed) are provided in Table 3. For formulation AH, a high-fat meal resulted in an ~15% increase in dolutegravir AUC_{0-\infty} and AUC_{0-t} values and an ~30% decrease in lamivudine C_{max}. For formulation AK, the high-fat meal resulted in an ~32% increase in dolutegravir AUC_{0-\infty} and AUC_{0-t}, an ~21% increase in dolutegravir C_{max}, and an ~30% decrease in lamivudine C_{max}. For both formulations, dolutegravir t_{max} was prolonged from 1.5 to 5 hours. Lamivudine t_{max} was prolonged from 1 to 3.5 hours for formulation AH and from 1 to 2.75 hours for formulation AK.

Adverse Events
Single-dose administration of both formulations AH and AK was well tolerated. There were no deaths or serious AEs. Eighteen subjects (24%) had AEs with formulation AH, 12 subjects (16%) had AEs with formulation AK, and 29 subjects (19%) had AEs with the reference treatment (combination of subjects from part 1 and part 2). Most AEs were mild. Drug-related AEs were similar across the treatment groups and in the fed versus fasted states (Table 4). Headache was the only drug-related AE reported in more than 1% of subjects.

Two subjects in part 1 and 1 subject in part 2 had AEs leading to discontinuation and withdrawal. In part 1, 1 subject experienced a grade 1 ALT elevation (96 IU/L; normal range 21 to 72 IU/L), which was deemed not related to study drug (formulation AH). The ALT value returned to normal by study day 21. Also in part 1, 1 subject experienced grade 1 vomiting that occurred within 4 hours of formulation AH administration and that was related to intravenous catheter insertion. In part 2, 1 subject experienced grade 1 creatinine elevation (132.6 µmol/L; normal range 44.2 to 114.9 µmol/L) on day 7 after receiving a single dose of formulation AK. This AE was due to the use of creatine and protein supplements and was deemed unrelated to study drug.

There were no trends in clinical laboratory evaluations, vital signs, or hematology parameters. ECG findings were either normal or were abnormal (outside of reference ranges) but not considered clinically significant.

Discussion
Two-drug, fixed-dose combination tablets have the potential to decrease cumulative drug exposure, and perhaps toxicity, as compared with 3-drug regimens. Streamlined treatment regimens, especially single-tablet regimens, may improve treatment compliance. Because coadministration of single-entity tablets of dolutegravir and lamivudine were recently demonstrated to be well tolerated and effective for treating HIV-1,25 the objective of the current study was to evaluate the
Table 3. Statistical Comparison of Plasma Dolutegravir and Lamivudine PK Parameters for Food Effect Assessment

| Parameter | Statistic | Formulation AH (Part 1) | Formulation AK (Part 2) |
|-----------|-----------|-------------------------|-------------------------|
|           | Fasted (n = 16) | Fed (n = 16) | GLS Mean Ratio (90% CI) [%CVw] | Fasted (n = 16) | Fed (n = 16) | GLS Mean Ratio (90% CI) [%CVw] |
| **Dolutegravir** | | | | | | |
| AUC<sub>0-22h</sub>, h·µg/mL | Mean (SD) | 57.363 (16.522) | 73.310 (14.520) | GLS Mean Ratio (90% CI) | 1.1545 (1.0208, 1.3058) | 60.907 (20.104) | 78.189 (17.264) | 1.3256 (1.1837, 1.4845) |
| | Adjusted geometric mean | 62.344 | 71.978 | 1.1545 | | 57.566 | 76.428 | | |
| AUC<sub>0-t</sub>, h·µg/mL | Mean (SD) | 55.217 (15.701) | 70.402 (13.155) | GLS Mean Ratio (90% CI) | 1.1481 (1.0154, 1.2982) | 58.232 (18.949) | 74.125 (14.768) | 1.3176 (1.1750, 1.4775) |
| | Adjusted geometric mean | 60.321 | 69.256 | 1.1481 | | 55.218 | 72.755 | | |
| C<sub>max</sub>, µg/mL | Mean (SD) | 3.228 (0.996) | 3.866 (0.779) | GLS Mean Ratio (90% CI) | 1.0808 (0.9527, 1.2621) | 3.270 (1.045) | 3.830 (0.804) | 1.3256 (1.1837, 1.4845) |
| | Adjusted geometric mean | 3.507 | 3.790 | 1.0808 | | 3.101 | 3.752 | | |
| CL/F, L/h | Median (Min, Max) | 1.50 (0.500, 5.00) | 5.00 (2.00, 12.0) | Adjusted geometric mean | 3.017 (1.872, 4.496) | 1.50 (0.751, 3.00) | 5.00 (1.01, 8.00) | 2.500 (1.748, 3.751) |
| | Mean (SD) | 14.867 (2.277) | 14.582 (1.873) | 1.0991 | | 15.474 (2.652) | 15.677 (2.505) | | |
| t<sub>max</sub>, h | Median (Min, Max) | 1.50 (0.503, 5.00) | 5.00 (2.00, 12.0) | Adjusted geometric mean | 3.017 (1.872, 4.496) | 1.50 (0.751, 3.00) | 5.00 (1.01, 8.00) | 2.500 (1.748, 3.751) |
| | Mean (SD) | 14.867 | 14.465 | | | 15.263 | 15.492 | | |
| t<sub>½</sub>, h | Mean (SD) | 18.012 (4.8134) | 23.691 (4.451) | Adjusted geometric mean | 2.113 (1.500, 2.751) | 1.00 (0.503, 2.51) | 2.75 (1.00, 6.00) | 1.503 (0.998, 2.252) |
| | | 22.329 | 23.316 | | | 22.905 | 20.152 | | |
| **Lamivudine** | | | | | | |
| AUC<sub>0-22h</sub>, h·µg/mL | Mean (SD) | 12.930 (2.565) | 13.068 (2.354) | GLS Mean Ratio (90% CI) | 0.9577 (0.9126, 1.0049) | 14.883 (2.890) | 13.603 (2.798) | 0.9114 (0.8658, 0.9593) |
| | Adjusted geometric mean | 13.436 | 12.867 | 0.9577 | | 14.624 | 13.344 | | |
| AUC<sub>0-t</sub>, h·µg/mL | Mean (SD) | 12.783 (2.536) | 12.850 (2.332) | GLS Mean Ratio (90% CI) | 0.9524 (0.9086, 0.9983) | 14.715 (2.890) | 13.351 (2.769) | 0.9048 (0.8592, 0.9528) |
| | Adjusted geometric mean | 13.282 | 12.649 | 0.9524 | | 14.471 | 13.092 | | |
| C<sub>max</sub>, µg/mL | Mean (SD) | 3.270 (0.906) | 2.554 (0.478) | GLS Mean Ratio (90% CI) | 0.7097 (0.6474, 0.7779) | 3.778 (1.241) | 2.576 (0.895) | 0.6826 (0.5861, 0.7950) |
| | Adjusted geometric mean | 3.541 | 2.513 | 0.7097 | | 3.582 | 2.445 | | |
| CL/F, L/h | Median (min, max) | 24.112 (4.8134) | 23.691 (4.451) | Adjusted geometric mean | 1.0442 (0.9951, 1.0957) | 20.802 (3.617) | 22.905 (4.515) | 1.0972 (1.0424, 1.1550) |
| | Mean (SD) | 22.329 | 23.316 | | | 20.489 | 22.481 | | |
| t<sub>max</sub>, h | Median (min, max) | 1.00 (0.500, 2.00) | 3.50 (1.01, 5.00) | Adjusted geometric mean | 2.113 (1.500, 2.751) | 1.00 (0.503, 2.51) | 2.75 (1.00, 6.00) | 1.503 (0.998, 2.252) |
| | Mean (SD) | 18.014 (4.625) | 19.918 (5.820) | 1.0382 | | 18.697 (5.558) | 20.152 (4.032) | | |

AUC indicates area under the concentration-time curve; CL/F, apparent clearance; C<sub>max</sub>, peak concentration; GLS, geometric least squares; %CVw, within-subject coefficient of variation expressed as a percentage; PK, pharmacokinetic; t<sub>max</sub>, time to C<sub>max</sub>; t<sub>½</sub>, half-time of elimination.

Note: The adjusted geometric mean is the anti-log of the adjusted mean (ls-mean) of log transformed values, where ls-mean can be defined as a linear combination (sum) of the estimated effects from a linear model. GLS mean ratios were calculated as test (fed) vs reference (fasted). Fasted results are given for subjects administered formulation AH or AK after at least a 10-hour fast, and fed results are given for subjects administered formulation AH or AK with a standard high-fat meal.

<sup>a</sup> For part 1, the population number (n = 16) is representative of the subjects used to calculate the geometric mean for subject-matched analysis. Arithmetic mean values for PK parameters were calculated from the total population of 76 subjects (n = 76).

<sup>b</sup> Value given as estimated median difference, calculated as Test – Reference (90% confidence interval of the difference).
Table 4. Summary of Drug-Related Adverse Events

|                      | Reference | AH (fasted) | AK (fasted) | AH (fed) | AK (fed) |
|----------------------|-----------|-------------|-------------|----------|----------|
|                      | N = 150   | N = 76      | N = 75      | N = 16   | N = 16   |
| n ( % )              | n ( % )   | n ( % )     | n ( % )     | n ( % )  | n ( % )  |
| Any event            | 8 (5)     | 5 (7)       | 5 (7)       | 0        | 0        |
| Headache             | 3 (2)     | 4 (5)       | 2 (3)       | 0        | 0        |
| Dizziness            | 2 (1)     | 0           | 0           | 0        | 0        |
| Diarrhea             | 1 (1)     | 0           | 0           | 0        | 0        |
| Nausea               | 2 (1)     | 0           | 0           | 0        | 0        |
| Vomiting             | 1 (1)     | 0           | 0           | 0        | 0        |
| Fatigue              | 0         | 0           | 1 (1)       | 0        | 0        |
| Abnormal dreams      | 0         | 1 (1)       | 0           | 0        | 0        |
| Dyspepsia            | 0         | 0           | 1 (1)       | 0        | 0        |
| Flatulence           | 0         | 0           | 1 (1)       | 0        | 0        |

Drug-related adverse events are defined as adverse events that were considered related to study drug administration and are reported for the safety population. Reference treatment refers to coadministration of 50 mg dolutegravir and 300 mg lamivudine; it combines all subjects from part 1 and part 2. AH and AK represent subjects receiving either formulation AH or AK in the fasted state (after at least a 10-hour fast), and fed represent subjects receiving either formulation AH or AK after a standard high-fat meal. Values are given as number of events (percentage of the population).

bioequivalence of 2 novel dolutegravir and lamivudine (50 mg and 300 mg, respectively) fixed-dose combination tablet formulations (AH and AK), using coadministration of 50 mg dolutegravir and 300 mg lamivudine tablets as the reference treatment. Safety and the potential effects of food were also evaluated.

Formulation AH exhibited lamivudine exposure that was similar to lamivudine exposure after coadministration of the single-entity tablets, as AUC_{0-∞}, AUC_{0-4}, and C_{max} GLS mean ratios and 90%CI values conformed to bioequivalence standards. However, dolutegravir exposure was consistently higher than the reference, and t_{max} was similar to the reference (Table 2), indicating a higher rate and extent of absorption of dolutegravir from formulation AH. Bioequivalence for this compound was therefore not achieved.

Formulation AK exhibited lamivudine AUC_{0-∞} and AUC_{0-4} values similar to the reference; however, C_{max} was approximately 32% higher. Dolutegravir exposure was similar to the reference as measured by AUC_{0-∞} and C_{max}. However, AUC_{0-4} was ~16% higher in the test formulation, and the upper 90%CI limit of the AUC_{0-4} GLS means ratio slightly exceeded the 1.2500 bioequivalence threshold, with a value of 1.2507. However, differences in test/reference AUC_{0-4} time windows may cause sufficient bias in the AUC_{0-4} geometric mean ratios to influence the determination of bioequivalence. A sensitivity analysis, which excluded 2 subjects with between-treatment differences in t_{last}, indicated that formulation AK was bioequivalent to the reference. Therefore, dolutegravir exposure from formulation AK can be considered bioequivalent to the reference.

The higher lamivudine C_{max} for formulation AK despite similar t_{max} values to the reference (Table 2) suggests a faster lamivudine absorption rate; however, potential reasons for this absorption change are unclear. Lamivudine is highly soluble over the physiologic pH range, and bioenhancement has not been observed. In addition, formulation AK has rapid and complete dissolution in vitro within 10 minutes (data not shown), and a previous relative bioavailability clinical study of the single-entity lamivudine demonstrated that a 100-mg capsule, a 100-mg tablet, and a 1 mg/mL alcohol-free oral solution were bioequivalent for AUC and C_{max}. Formulation AK exhibited lamivudine AUC_{0-∞} and AUC_{0-4} values similar to the reference; however, C_{max} was approximately 32% higher. Dolutegravir exposure was similar to the reference as measured by AUC_{0-∞} and C_{max}. However, AUC_{0-4} was ~16% higher in the test formulation, and the upper 90%CI limit of the AUC_{0-4} GLS means ratio slightly exceeded the 1.2500 bioequivalence threshold, with a value of 1.2507. However, differences in test/reference AUC_{0-4} time windows may cause sufficient bias in the AUC_{0-4} geometric mean ratios to influence the determination of bioequivalence. A sensitivity analysis, which excluded 2 subjects with between-treatment differences in t_{last}, indicated that formulation AK was bioequivalent to the reference. Therefore, dolutegravir exposure from formulation AK can be considered bioequivalent to the reference.

Although the underlying mechanism of faster lamivudine absorption rate remains unknown, the higher lamivudine C_{max} is not considered clinically significant. Lamivudine AUC is considered the best plasma pharmacokinetic predictor of efficacy, and AUC values were bioequivalent (Table 2). Additionally, long-term (24 weeks) dose ranging studies with lamivudine have not indicated a dose-related increased risk of AEs or laboratory abnormalities with doses up to 840 mg daily for a 70-kg subject. Finally, multiple phase 3 studies have failed to demonstrate any dose-related increases in the overall incidence of AEs, and there were no significant safety or efficacy differences between the standard lamivudine 300 mg/d regimen and a higher 600 mg/d regimen.

A food effect for both dolutegravir and lamivudine exposure parameters was noted (Table 3), with administration of a high-fat meal increasing dolutegravir AUC for formulation AH by ~15% and for formulation AK..
by ~32%, increasing dolutegravir $C_{\text{max}}$ for formulation AK by ~21%, and reducing lamivudine $C_{\text{max}}$ for both formulations by ~30%. These increases in dolutegravir AUC and $C_{\text{max}}$ and decreases in lamivudine $C_{\text{max}}$ in response to food are consistent with the known effect of food on the individual components, which is not expected to impact safety or efficacy.

Single doses of the experimental formulations were well tolerated. Most subjects did not report any AEs, and most of the reported AEs were mild. The drug-related AEs were consistent with the known profiles of dolutegravir and lamivudine. Headache, a known common side effect of both drugs, was the only drug-related adverse event that occurred in more than 1% of the study population (3% to 5%). These results support the safety and tolerability of the combination formulations.

In conclusion, although single doses of both formulations AH and AK were safe and well tolerated, the pharmacokinetic data demonstrate that formulation AK is most comparable to the treatment regimen used in the GEMINI studies. Formulation AK met bioequivalence standards for dolutegravir AUC and $C_{\text{max}}$ and for lamivudine AUC when compared with coadministration of 50-mg dolutegravir tablets and 300-mg lamivudine tablets. A higher lamivudine $C_{\text{max}}$, which reflects differences in the rate but not the extent of absorption, was observed for formulation AK but is not expected to significantly affect patient safety or antiviral efficacy based on historical data. Taken together, the data from this bioequivalence and food-effect study provide an acceptable pharmacokinetic bridge between the formulation AK fixed-dose combination tablet and the single-drug entities used in the GEMINI-1 and GEMINI-2 studies. These results supported further development of formulation AK, which was recently approved in the United States and the European Union as Dovato, a 2-drug, fixed-dose combination therapy for the treatment of patients with HIV-1.

Conflicts of Interest

T.P.D., K.B., and J.K. are GlaxoSmithKline (GSK) employees and may own GSK stock. K.P. is a contract worker employed by GSK and may own GSK stock. C.S., A.W., and S.J. are GSK employees. C.F., S.Y., and Z.Z. are employees of PAREXEL International. K.A. and A.T. are ViiV Healthcare employees and may own GSK stock.

Acknowledgments

The study was funded by ViiV Healthcare. The authors thank Keri Hamilton (Nuventra, Inc) for her help in writing this article. K.H. has no competing conflicts of interest.

References

1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2018. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed September 6, 2019.
2. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808-816.
3. van Galen KA, Nellen JF, Nieuwkerk PT. The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-analysis. AIDS Res Treat. 2014;2014:967073.
4. Hirasen K, Evans D, Maskew M, et al. The right combination—treatment outcomes among HIV-positive patients initiating first-line fixed-dose antiretroviral therapy in a public sector HIV clinic in Johannesburg, South Africa. Clin Epidemiol. 2017;10:17-29.
5. Kauf TL, Davis KL, Earnshaw SR, Davis EA. Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adher. 2012;6:155-164.
6. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254-258.
7. Brenner BG, Wainberg MA. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res. 2017;239:1-9.
8. Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55(10):4552-4559.
9. Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7(5):390-400.
10. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813-821.
11. Castellino S, Moss L, Wagner D, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57(8):3536-3546.
12. Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41(2):353-361.
13. Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52(11):981-994.
14. Lepist EI, Zhang X, Hao J, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int. 2014;86(2):350-357.
15. Song IH, Zong J, Borland J, et al. The effect of solute-gravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr. 2016;72(4):400-407.
16. Quercia R, Perno CF, Koteff J, et al. Twenty-five years of lamivudine: current and future use for the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2018;78(2):125-135.
17. Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2010;6(1):105-114.
18. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36(1):41-66.
19. van Leeuwen R, Lange JM, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS. 1992;6(12):1471-1475.
20. Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol. 1995;35(12):1174-1180.
21. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40(6):1514-1519.
22. Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther. 1996;59(5):550-558.
23. Adkison K, Wolstenholme A, Lou Y, et al. Effect of sorbitol on the pharmacokinetic profile of lamivudine oral solution in adults: an open-label, randomized study. Clin Pharmacol Ther. 2018;103(3):402-408.
24. Cahn P, Rolon MJ, Figueroa MI, Gun A, Patterson P, Sued O. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients. 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir Lamivudine) study. J Int AIDS Soc. 2017;20(1):21678-21678.
25. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143-155.
26. GSK CSR. Study 204993: A phase I, relative oral bioavailability study of different fixed dose combinations of dolutegravir and lamivudine in healthy subjects. 2016. https://s3.amazonaws.com/ctr-gsk-7381/204993/0e2d3202-e363-402a-a60d-d2082ac2f8ea/67ce1f49-088a-4fdd-8acf-8f3b38a32f84/gsk-204993-Clinical-Study-Result-Summary-v1.pdf. Accessed September 6, 2019.
27. FDA Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies. 2002. https://www.fda.gov/media/70945/download. Accessed September 6, 2019.
28. Song I, Weller S, Patel J, et al. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. Eur J Clin Pharmacol. 2016;72(6):665-670.
29. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm. 1987;15(6):657-680.
30. Fisher D, Kramer W, Burmeister Getz E. Evaluation of a scenario in which estimates of bioequivalence are biased and a proposed solution: tu0 (Common). J Clin Pharmacol. 2016;56(7):794-800.
31. Dezani A, Pereira T, Caffaro A, Reis J, Serra C. Equilibrium solubility versus intrinsic dissolution: characterization of lamivudine, stavudine and zidovudine for BCS classification. Braz J Pharm Sci. 2013;49(4):853-863.
32. Fletcher CV, Kawle SP, Kakuda TN, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS. 2000;14(14):2137-2144.
33. Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Ann Intern Med. 1996;125(3):161-172.
34. Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996;276(2):111-117.
35. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med. 1995;333(25):1662-1669.
36. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012;56(3):1627-1629.
37. Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. *J Acquir Immune Defic Syndr*. 2014;66(4):393-398.

38. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. *Lancet*. 2013;381(9868):735-743.